|
|
Article: Sirion Therapeutics Acquires U.S. License to Develop New Treatment for Viral Eye Infection.
- Article from:
- PR Newswire
- Article date:
- January 17, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., Jan. 17 /PRNewswire/ -- Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceuticals company, announced today that it has reached an exclusive licensing agreement with Laboratoires Thea of France for the U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for the treatment of certain viral and superficial eye infections. The product is currently marketed by Thea in Europe under the brand name of Virgan(R).
"We are excited to acquire the U.S. rights to this product," said Roger Vogel, Sirion's Chief Medical Officer. "Topical ganciclovir has been available in Europe for the treatment of ocular viral infections for ...
Related newspaper, magazine, and journal articles:
|
|
Article: Sirion Therapeutics, Inc. Combines With Tenby ...
PR Newswire;
September 18, 2006 ;
700+ words
... ... announced today its acquisition of Sirion Therapeutics, Inc. as a wholly owned subsidiary ... Barry Butler, President and CEO of Sirion Therapeutics, Inc., has been appointed to ... MD, Chief Medical Officer of Sirion Therapeutics, and Barry Butler have been appointed ...
|
|